Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned

Annals of Oncology

Volumn 27, Issue , 2016, Pages i66-i71

  Friedlander, M ^a   Mercieca Bebber, R L ^a,b   King, M T ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

HRQOL; Ovarian cancer; Patient reported outcomes

Indexed keywords

BEVACIZUMAB; DOXORUBICIN; OLAPARIB; PLACEBO; PLATINUM COMPLEX; ANTINEOPLASTIC AGENT;

ABDOMINAL DISEASE; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHECKLIST; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL STUDY; DIARRHEA; DRUG EFFICACY; EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY MAGNITUDE OF CLINICAL BENEFIT SCALE; FACIT OVARIAN SYMPTOM INDEX; FEMALE; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL ASSESSMENT OF CANCER THERAPY OVARIAN; FUNCTIONAL ASSESSMENT OF CANCER THERAPY OVARIAN SYMPTOM INDEX; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEALTH CARE DELIVERY; HEALTH PROMOTION; HIGH RISK PATIENT; HUMAN; LABELLING CLAIMS; MAGNITUDE OF CLINICAL BENEFIT SCALE; MAINTENANCE THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; OVARIAN CANCER MODULE 28; OVARY CANCER; OVERALL SURVIVAL; PATIENT REPORTED OUTCOMES; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; QUALITY OF LIFE QUESTIONNAIRE CORE 30; QUESTIONNAIRE; RATING SCALE; RECURENT OVARIAN CANCER; RECURRENT OVARIAN CANCER; REFRACTORY OVARIAN CANCER; RESISTANT OVARIAN CANCER; STANDARD; STOMATITIS; TREATMENT OUTCOME; TRIAL OUTCOME INDEX MEAN SCORE; VOLUNTARY REPORTING; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; MORTALITY; OVARY TUMOR; PATIENT-REPORTED OUTCOME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; OVARIAN NEOPLASMS; PATIENT REPORTED OUTCOME MEASURES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84966364944     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw080     Document Type: Article

References (28)

1. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
2. Belton AL, Saini S, Liebermann K et al. Tumour size measurement in an oncology clinical trial: comparison between off-site and on-site measurements. Clin Radiol 2003; 58: 311-314.
3. Erasmus JJ, Gladish GW, Broemeling L et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 2003; 21: 2574-2582.
4. Guppy AE, Rustin GJ. CA125 response: can it replace the traditional response criteria in ovarian cancer? Oncologist 2002; 7: 437-443.
5. Au HJ, Ringash J, Brundage M et al. Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG. Expert Rev Pharmacoecon Outcomes Res 2010; 10: 119-128.
6. Brundage M, Blazeby J, Revicki D et al. Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards. Qual Life Res 2013; 22: 1161-1175.
7. Davis A, Tinker AV, Friedlander M. 'Platinum resistant' ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol Oncol 2014; 133: 624-631.
8. Colombo N, Kutarska E, Dimopoulos M et al. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J Clin Oncol 2012; 30: 3841-3847.
9. Aghajanian C, Goff B, Nycum LR et al. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol 2015; 10: 10-16.
10. Havrilesky LJ, Abernethy AP. Quality of life in ICON7: need for patients' perspectives. Lancet Oncol 2013; 14: 183-185.
11. Efficace F, Jacobs M, Pusic A et al. Patient-reported outcomes in randomised controlled trials of gynaecological cancers: investigating methodological quality and impact on clinical decision-making. Eur J Cancer 2014; 50: 1925-1941.
12. Osoba D, Bezjak A, Brundage M et al. Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 2005; 41: 280-287.
13. Pujade-Lauraine E, Hilpert F, Weber B et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA openlabel randomized phase III trial. [Erratum appears in J Clin Oncol. 2014 Dec 10;32 (35):4025]. J Clin Oncol 2014; 32: 1302-1308.
14. Stockler MR, Hilpert F, Friedlander M et al. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol 2014; 32: 1309-1316.
15. Reed NS, Poole CJ, Coleman R et al. A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: a study by the Scottish Gynaecological Cancer Trials Group (SGCTG). Eur J Cancer 2006; 42: 179-185.
16. Kaye SB, Lubinski J, Matulonis U et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADPribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 2012; 30: 372-379.
17. Brundage M, Bass B, Davidson J et al. Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers. Qual Life Res 2011; 20: 653-664.
18. Joly F, Vardy J, Pintilie M, Tannock IF. Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer. Ann Oncol 2007; 18: 1935-1942.
19. Bylicki O, Gan HK, Joly F et al. Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy. Ann Oncol 2015; 26: 231-237.
20. Calvert M, Blazeby J, Altman DG et al. Reporting of patient-reported outcomes in randomized trials: The consort PRO extension. JAMA 2013; 309: 814-822.
21. FDA. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Silver Spring, MD: Food and Drug Administration. 2009.
22. Cherny NI, Sullivan R, Dafni U et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015; 26: 1547-1573.
23. Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in platinumsensitive relapsed ovarian cancer. N Engl J Med 2012; 366: 1382-1392.
24. Chan A-W, Tetzlaff JM, Altman DG et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 2013; 158: 200-207.
25. Calvert M, Kyte D, Duffy H et al. Patient reported outcome (PRO) assessment in clinical trials: a systematic review of guidance for trial protocol writers. PLoS ONE 2014; 9: e110216.
26. Friedlander M, Trimble E, Tinker A et al. Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer 2011; 21: 771-775.
27. Herzog TJ, Armstrong DK, Brady MF et al. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. Gynecol Oncol 2014; 132: 8-17.
28. Stuart GC, Kitchener H, Bacon M et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 2011; 21: 750-755.